Anti-Obesity Drugs Market to Gain Highest Future Growth by 2026Posted by Mangesh on May 24th, 2019 Anti-obesity drugs are pharmacological agents that are used to lose cholesterol and reduce the body weight. These drugs generally show their action by altering the fundamental functioning of the normal body by utilization of calories or by altering the appetite. Factors such as increasing prevalence of obesity, adoption of sedentary lifestyle, increasing aging population, and chronic nature of disease drive the market growth. However, side effects of the drugs and limited availability of combination therapy restrain the market growth. Moreover, introduction of novel anti-obesity drugs and untapped opportunities in emerging nations increase opportunities for the market growth during the forecast period. Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/4170 The anti-obesity drugs market is segmented on the basis of drug class, medication, type, and region. On the basis of drug class it is segmented into peripherally acting anti-obesity drugs and centrally acting anti-obesity drugs. On the basis of medication, it is segmented into monotherapies and polytherapies. On the basis of type, it is segmented into prescription drugs and OTC drugs. Geographically the market has been analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). Key players in the market include Arena Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Alizyme plc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Pfizer Inc, Shionogi Inc., Merck & Co., Inc., and Norgine B.V. Get a purchase enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/4170 Key Benefits:
Like it? Share it! More by this author |